Health Catalyst (HCAT)
(Delayed Data from NSDQ)
$6.03 USD
+0.43 (7.68%)
Updated Apr 24, 2024 04:00 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Health Catalyst (HCAT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.14 | $16.00 | $8.00 | 101.33% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Health Catalyst comes to $12.14. The forecasts range from a low of $8.00 to a high of $16.00. The average price target represents an increase of 101.33% from the last closing price of $6.03.
Analyst Price Targets (14)
Broker Rating
Health Catalyst currently has an average brokerage recommendation (ABR) of 1.59 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.47 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, 12 are Strong Buy, representing 70.59% of all recommendations. A month ago, Strong Buy represented 76.47%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 13 | 13 | 13 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.59 | 1.59 | 1.47 | 1.47 | 1.47 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Hold | Hold |
3/5/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
3/1/2024 | Stephens | Jeffrey Garro | Hold | Hold |
2/23/2024 | Raymond James | John W Ransom | Hold | Hold |
2/23/2024 | Canaccord Genuity | Richard Close | Strong Buy | Strong Buy |
2/23/2024 | Evercore Partners | Elizabeth Anderson | Strong Buy | Strong Buy |
2/9/2024 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
1/26/2024 | Guggenheim Securities | Jack D Wallace | Hold | Strong Buy |
1/7/2024 | BTIG | David M Larsen | Strong Buy | Strong Buy |
12/22/2023 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.59 |
ABR (Last week) | 1.59 |
# of Recs in ABR | 17 |
Average Target Price | $12.14 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | 0.03 |